GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
M

MicroTech Medical (Hangzhou) Co 2235.HK · HKD

Health Care · HKEX · 🇭🇰 Hong Kong

Compare

6.79

+2.88%

Close of 9 Nov 2026, in HKD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CNY, from our data supplier.

FY2025

Revenue

CN¥769.4m

FY2019FY2025

Net income

CN¥46.7m

FY2019FY2025

Free cash flow

−CN¥7.1m

FY2019FY2025

Shareholders' equity

CN¥2.35bn

FY2019FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019
RevenueCN¥769.4mCN¥345.6mCN¥248.3mCN¥202.1mCN¥176.3mCN¥87.6mCN¥60.4m
Gross profitCN¥416.2mCN¥182.8mCN¥123.2mCN¥92.7mCN¥82.5mCN¥42.5mCN¥28.0m
Research and developmentCN¥88.9mCN¥76.6mCN¥70.1mCN¥35.6mCN¥17.3mCN¥95.5mCN¥58.3m
Operating incomeCN¥51.2m−CN¥62.5m−CN¥120.3m−CN¥37.5m−CN¥70.1m−CN¥170.5m−CN¥97.0m
Net incomeCN¥46.7m−CN¥63.1m−CN¥125.0m−CN¥40.8m−CN¥56.1m−CN¥140.9m−CN¥91.5m
Diluted earnings per share0.12-0.15-0.29-0.09-0.15-0.33-0.22

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Total assetsCN¥2.69bnCN¥2.50bnCN¥2.51bnCN¥2.67bnCN¥2.71bnCN¥905.0mCN¥308.2m
Cash and short-term investmentsCN¥1.80bnCN¥1.99bnCN¥2.20bnCN¥2.38bnCN¥2.50bnCN¥762.6mCN¥192.0m
Total liabilitiesCN¥334.2mCN¥199.9mCN¥113.8mCN¥95.5mCN¥96.0mCN¥56.8mCN¥55.8m
DebtCN¥106.3mCN¥165,600CN¥643,400CN¥716,200CN¥255,000CN¥126,000CN¥10.0m
Shareholders' equityCN¥2.35bnCN¥2.30bnCN¥2.40bnCN¥2.58bnCN¥2.62bnCN¥848.2mCN¥252.4m
Shares outstanding382m422m426m450m386m424m424m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Cash from operationsCN¥37.0m−CN¥140.5m−CN¥178.1m−CN¥125.4m−CN¥51.5m−CN¥11.1m−CN¥20.9m
Capital spending−CN¥44.1m−CN¥96.9m−CN¥33.4m−CN¥34.7m−CN¥21.8m−CN¥29.9m−CN¥35.5m
Free cash flow−CN¥7.1m−CN¥237.4m−CN¥211.5m−CN¥160.0m−CN¥73.3m−CN¥41.1m−CN¥56.4m
Dividends paid−CN¥25,761−CN¥771,950—————

Latest quarters

By quarter end

Jun 2026Dec 2025Jun 2025Dec 2024Jun 2024Dec 2023Jun 2023Dec 2022
RevenueCN¥475.5mCN¥483.0mCN¥143.2mCN¥194.8mCN¥150.8mCN¥142.4mCN¥129.0mCN¥118.5m
Gross profitCN¥274.4mCN¥268.2mCN¥74.0mCN¥99.0mCN¥83.8mCN¥64.6mCN¥67.1mCN¥55.8m
Operating incomeCN¥46.9mCN¥54.0m−CN¥1.4m−CN¥24.7m−CN¥37.7m−CN¥101.6m−CN¥77.4m−CN¥88.0m
Net incomeCN¥46.2mCN¥49.4m−CN¥1.3m−CN¥25.4m−CN¥37.7m−CN¥106.4m−CN¥21.7m−CN¥31.6m
Diluted earnings per share0.110.13-0.00-0.06-0.09-0.25-0.05-0.07
Cash from operations—CN¥32.0mCN¥5.0mCN¥89.0m−CN¥44.0m−CN¥141.0m−CN¥37.0m−CN¥107.0m
Capital spending—−CN¥6.0m−CN¥42.0m−CN¥48.0m−CN¥48.0m−CN¥28.0m−CN¥4.0m−CN¥18.0m
Free cash flow—CN¥26.0m−CN¥37.0mCN¥41.0m−CN¥92.0m−CN¥169.0m−CN¥41.0m−CN¥125.0m
Total assetsCN¥2.72bnCN¥2.69bnCN¥2.57bnCN¥2.15bnCN¥2.17bnCN¥2.16bnCN¥2.64bnCN¥2.67bn
Cash and short-term investmentsCN¥1.79bnCN¥1.80bnCN¥2.01bnCN¥1.71bnCN¥1.81bnCN¥1.89bnCN¥2.39bnCN¥2.38bn
DebtCN¥128.2mCN¥106.3mCN¥35.9mCN¥4.2mCN¥20.4mCN¥5.1mCN¥550,727CN¥834,479
Shareholders' equityCN¥2.37bnCN¥2.35bnCN¥2.29bnCN¥1.97bnCN¥2.01bnCN¥2.06bnCN¥2.55bnCN¥2.58bn

Financial ratios

Data as of 26 Oct 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Gross margin54.1%52.9%49.6%45.9%46.8%48.5%
Operating margin2.7%-38.1%-78.6%-69.3%-31.8%-194.6%
Net margin6.1%-18.3%-50.3%-20.2%-31.8%-160.8%
Return on equity2.0%-3.2%-6.1%-1.6%-2.1%-16.6%
Return on assets1.7%-2.9%-5.8%-1.5%-2.1%-15.6%
Free cash flow yield2.7%-1.3%-4.3%-2.6%-1.0%0.6%
Revenue growth91.2%39.2%43.1%14.6%101.1%45.1%
Earnings growth-163.6%-49.5%256.7%-27.3%-60.2%53.9%
Current ratio6.39x11.41x21.67x26.61x27.12x14.12x
Debt to equity0.05x0.00x0.00x0.00x0.00x0.00x
Equity ratio87.2%92.0%95.5%96.4%96.5%93.7%
Interest coverage39.95x-194.77x-623.55x-818.64x-2831.53x-475.55x
R&D as a share of sales11.6%22.2%28.2%17.6%9.8%108.9%
Buybacks as a share of market value9.6%0.8%5.5%-16.6%8.8%0.0%

Growth per year

Compound annual rate

3 years5 years10 years
Revenue56.2%54.4%—

Average margins

Over each period

1 year3 years5 years10 years
Gross margin53.7%52.1%51.4%—
Operating margin-1.0%-10.8%-22.4%—
Net margin-1.5%-11.6%-20.7%—

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021
Price to earnings58.2-38.4-19.8-98.3-159.8
Price to sales3.57.010.019.950.9

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.